Biologics are a special type of powerful drug that slows or stops damaging inflammation. The global biologics market is anticipated to grow significantly over the forecast period. The major factors such as sizable investments in research and developmental activities in the biotechnology and pharmaceutical sector and the increasing demand for novel therapies for several rare diseases are boosting the growth of the global biologics market progressively.
Furthermore, recent researches in new therapies and combination therapies have formed the efficiency of biologics for treating a wide range of chronic diseases such as cancer, rheumatoid arthritis, macular degeneration. In addition to this, recombinant DNA technology has been expanding the potential of the biologics market. Moreover, increasing approval of biologics by several regulatory agencies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) further largely supporting the growth of the global Biologics market.
Covid-19 Impact on Biologics Market
In addition, the current Biologics Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Biologics Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Biologics Market Segment Overview
According to Product, the Monoclonal Antibodies segment is projected to lead the global Biologics market over the forecast period. The growth of this segment is primarily attributed to the growing demand for personalized therapies in several regions. Additionally, widespread researches in antibodies to discover targeted therapies for various diseases, such as different types of cancers, infections, and many immunological disorders, are anticipated to fuel the growth of the market. As well, the Vaccines segment is projected to show the fastest growth in the forthcoming years due to its usage as a preventative tool in infectious diseases. Based on Application, the Oncology segment is accounted for the maximum share of the market. This is due to the growing prevalence of cancer coupled with the presence of different R&D projects. These projects contain gene therapies and antisense therapies for cancer abolition.
Biologics Market, By Product
· Monoclonal Antibodies
· Vaccines
· Cell Therapy
· Recombinant Hormones/Proteins
· Gene Therapy
Biologics Market, By Application
· Infectious Diseases
· Oncology
· Immunology
· Autoimmune Diseases
Biologics Market Regional Overview
In terms of geography, North America is projected to occupy the largest revenue share of the global Biologics market over the forecast period. The intensive R&D activities, advanced drug formulations, and growing clinical trials focused on large-molecule drug discovery are some favorable factors that extend the market’s growth in this region. Likewise, Europe is the second significant region for Biologics. On the other hand, the market in the Asia Pacific is expected to witness remarkable growth in the coming period. An extensive patient base in need of novel therapies for chronic diseases and the low cost involved in drug manufacturing are major factors that boosting the growth of the market in the Asia Pacific region. Additionally, the global pharmaceutical companies setting up their biologics production facilities in emerging markets, mainly China, is likely to boost the regional market.
Biologics Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Biologics Market Competitor overview
Some key developments and strategies adopted by manufacturers in Biologics are highlighted below.
· In August 2021, Evotec SE announced the opening of its J.POD 1 late-stage clinical and commercial biologics biomanufacturing facility, in Redmond, Wash., part of Just - Evotec Biologics' J.DESIGN platform, which integrates data analytics and machine learning for the discovery, development, and manufacturing of biologic drugs.
· In August 2021, AGC Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO), announced that it has finalized the acquisition of a commercial manufacturing facility in Longmont, Colo., previously owned by Novartis Gene Therapies. The facility significantly expands AGC Biologics’ capacity for producing cell and gene therapies, with additional space to expand.
Biologics Market, Key Players
· AbbVie Inc.
· AstraZeneca
· Amgen Inc.
· F. Hoffmann-La Roche Ltd
· Bayer AG
· Sanofi
· Eli Lilly and Company
· GlaxoSmithKline Plc.
· Pfizer Inc.
· Merck & Co., Inc.
· Novartis AG
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Biologics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product
- 5.2.1. Monoclonal Antibodies
- 5.2.2. Vaccines
- 5.2.3. Cell Therapy
- 5.2.4. Recombinant Hormones/Proteins
- 5.2.5. Gene Therapy
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Infectious Diseases
- 5.3.2. Oncology
- 5.3.3. Immunology
- 5.3.4. Autoimmune Diseases
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Biologics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product
- 6.2.1. Monoclonal Antibodies
- 6.2.2. Vaccines
- 6.2.3. Cell Therapy
- 6.2.4. Recombinant Hormones/Proteins
- 6.2.5. Gene Therapy
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Infectious Diseases
- 6.3.2. Oncology
- 6.3.3. Immunology
- 6.3.4. Autoimmune Diseases
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Biologics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product
- 7.2.1. Monoclonal Antibodies
- 7.2.2. Vaccines
- 7.2.3. Cell Therapy
- 7.2.4. Recombinant Hormones/Proteins
- 7.2.5. Gene Therapy
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Infectious Diseases
- 7.3.2. Oncology
- 7.3.3. Immunology
- 7.3.4. Autoimmune Diseases
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Biologics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product
- 8.2.1. Monoclonal Antibodies
- 8.2.2. Vaccines
- 8.2.3. Cell Therapy
- 8.2.4. Recombinant Hormones/Proteins
- 8.2.5. Gene Therapy
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Infectious Diseases
- 8.3.2. Oncology
- 8.3.3. Immunology
- 8.3.4. Autoimmune Diseases
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Biologics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product
- 9.2.1. Monoclonal Antibodies
- 9.2.2. Vaccines
- 9.2.3. Cell Therapy
- 9.2.4. Recombinant Hormones/Proteins
- 9.2.5. Gene Therapy
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Infectious Diseases
- 9.3.2. Oncology
- 9.3.3. Immunology
- 9.3.4. Autoimmune Diseases
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. AbbVie Inc.
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. AstraZeneca
- 10.6. Amgen Inc.
- 10.7. F. Hoffmann-La Roche Ltd
- 10.8. Bayer AG
- 10.9. Sanofi
- 10.10. Eli Lilly and Company
- 10.11. GlaxoSmithKline Plc.
- 10.12. Pfizer Inc.
- 10.13. Merck & Co., Inc.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
